.svg){kind=small}
Where to Buy
Beneleaves is stocked at 93 licensed dispensaries across Ohio, with the deepest coverage in Columbus, Cincinnati, Cleveland, Dayton, and Lorain. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
In September 2026, Beneleaves concentrated 89.20% of sales in Capsules, where year-over-year growth reached 49.72% despite a month-over-month decline of 7.25%, while Topical held 7.52% share with 81.36% YoY growth and an 11.61% MoM increase. Edible expanded to 2.81% share after an 862.96% YoY surge and a 196.53% MoM jump, whereas Vapor Pens contracted to 0.47% share with YoY down 74.75% and MoM down 40.45%; taken together with a 13.02% YoY drop in average price to $26.14, the pattern implies mix-driven unit velocity gains concentrated in Capsules and new trial in Edible, partially offset by price compression and a deliberate de-emphasis of Vapor Pens.
With Capsules ranked 1 in Ohio and accounting for 89.20% of volume, the 7.25% MoM dip alongside 49.72% YoY growth suggests saturation risk at the category core even as the brand deepens penetration; concurrently, Topical’s 11.61% MoM rise and Edible’s 196.53% MoM spike indicate incremental entry points that reduce reliance on a single category. The 81.36% YoY increase in Topical and the sharp 862.96% YoY rise in Edible, paired with a portfolio-wide 13.02% price decrease, imply a positioning pivot toward accessible price tiers to accelerate trial in adjacencies while protecting leadership in Capsules.
Competitive Landscape
Beneleaves holds #1 in OH Capsules in September 2026 and is unchanged YoY from #1, while UB GOOD sits at #2 with sales up 55.4% YoY and Main Street Health is #3 with a 34.2% YoY lift; by contrast, Butterfly Effect - Grow Ohio declined 36.1% YoY at #4, indicating the gap below the top spot is widening even as growth pressure builds from #2. With Beneleaves also at #1 three months ago and peaking at #1 in September 2026, the flat YoY rank at #1 combined with double-digit competitor gains implies a defended leadership that relies on maintaining share efficiency rather than rank mobility, and any slip in velocity could convert competitor percentage growth into a rank risk.
Notable Products
Hybrid Unflavored RSO Capsules 11-Pack (110mg) posted the steepest decline at -35.5% MoM and slid to rank 7, while Indica Hypnos Capsules 11-Pack (440mg) fell -12.6% MoM at rank 4, indicating erosion in mid-tier capsule velocity. In contrast, Sativa Helios Capsules 11-Pack (440mg) climbed +19.0% MoM to hold rank 2, and the flagship Hybrid RSO Capsules 22-Pack (660mg) in rank 1 inched up +5.3% MoM on roughly $129,151, signaling that demand is concentrating at the premium and high-dosage end. With eight of the top ten SKUs in Capsules and two Topicals mixed performance (+5.7% at rank 8 versus -15.7% at rank 9), the pattern implies Beneleaves is consolidating around higher-potency capsule formats while pruning or repositioning smaller-count variants.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
